The thymosins-preclinical and clinical studies with fraction V and alpha-i

Richard V. Smalley, James E Talmadge, Robert K. Oldham, Gary B. Thurman

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Thus, in 193 patients treated with a variety of schedules and with doses ranging from 0.6 to 960 mg/m2, fraction 5 could be administered without toxicity other than the allergic reactions noted at high repeated doses with the intermittent schedule. Significant and reproducible biologic response modification as defined by T-cell quantitation (as determined by E-rosette assay and flourescent antibody assays for T-cell surface antigens) and by lymphocyte blastogenesis to suboptimal or optimal concentrations of PHA and Con A, as well as reactions to allogeneic antigens under a variety of suboptimal and optimal conditions in standard MLR assays, could not be demonstrated. Suppressor cell activity, although not directly assayed, was not observed. Three objective tumors responses were seen in patients with renal cell carcinoma but none were seen in an adequately studied number of patients with advanced breast carcinoma, non-oat cell lung cancer, melanoma, or colon carcinoma. Alpha-1 serum levels of 10 to 25 ng/ml were achieved within one hour of the administration of 60-150 mg/m2 fraction 5. These pharmacologic levels were maintained for several hours before falling off to baseline levels by 24 hours.

Original languageEnglish (US)
Pages (from-to)69-84
Number of pages16
JournalCancer Treatment Reviews
Volume11
Issue number1
DOIs
StatePublished - Jan 1 1984

Fingerprint

Thymosin
Appointments and Schedules
Accidental Falls
T-Lymphocytes
Surface Antigens
Lymphocyte Activation
Renal Cell Carcinoma
Melanoma
Lung Neoplasms
Hypersensitivity
Colon
Lymphocytes
Breast Neoplasms
Carcinoma
Antigens
Antibodies
Serum
Clinical Studies
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

The thymosins-preclinical and clinical studies with fraction V and alpha-i. / Smalley, Richard V.; Talmadge, James E; Oldham, Robert K.; Thurman, Gary B.

In: Cancer Treatment Reviews, Vol. 11, No. 1, 01.01.1984, p. 69-84.

Research output: Contribution to journalArticle

Smalley, Richard V. ; Talmadge, James E ; Oldham, Robert K. ; Thurman, Gary B. / The thymosins-preclinical and clinical studies with fraction V and alpha-i. In: Cancer Treatment Reviews. 1984 ; Vol. 11, No. 1. pp. 69-84.
@article{9e6c06fb41a1429b9f2ba89878c1ef34,
title = "The thymosins-preclinical and clinical studies with fraction V and alpha-i",
abstract = "Thus, in 193 patients treated with a variety of schedules and with doses ranging from 0.6 to 960 mg/m2, fraction 5 could be administered without toxicity other than the allergic reactions noted at high repeated doses with the intermittent schedule. Significant and reproducible biologic response modification as defined by T-cell quantitation (as determined by E-rosette assay and flourescent antibody assays for T-cell surface antigens) and by lymphocyte blastogenesis to suboptimal or optimal concentrations of PHA and Con A, as well as reactions to allogeneic antigens under a variety of suboptimal and optimal conditions in standard MLR assays, could not be demonstrated. Suppressor cell activity, although not directly assayed, was not observed. Three objective tumors responses were seen in patients with renal cell carcinoma but none were seen in an adequately studied number of patients with advanced breast carcinoma, non-oat cell lung cancer, melanoma, or colon carcinoma. Alpha-1 serum levels of 10 to 25 ng/ml were achieved within one hour of the administration of 60-150 mg/m2 fraction 5. These pharmacologic levels were maintained for several hours before falling off to baseline levels by 24 hours.",
author = "Smalley, {Richard V.} and Talmadge, {James E} and Oldham, {Robert K.} and Thurman, {Gary B.}",
year = "1984",
month = "1",
day = "1",
doi = "10.1016/0305-7372(84)90017-3",
language = "English (US)",
volume = "11",
pages = "69--84",
journal = "Cancer Treatment Reviews",
issn = "0305-7372",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - The thymosins-preclinical and clinical studies with fraction V and alpha-i

AU - Smalley, Richard V.

AU - Talmadge, James E

AU - Oldham, Robert K.

AU - Thurman, Gary B.

PY - 1984/1/1

Y1 - 1984/1/1

N2 - Thus, in 193 patients treated with a variety of schedules and with doses ranging from 0.6 to 960 mg/m2, fraction 5 could be administered without toxicity other than the allergic reactions noted at high repeated doses with the intermittent schedule. Significant and reproducible biologic response modification as defined by T-cell quantitation (as determined by E-rosette assay and flourescent antibody assays for T-cell surface antigens) and by lymphocyte blastogenesis to suboptimal or optimal concentrations of PHA and Con A, as well as reactions to allogeneic antigens under a variety of suboptimal and optimal conditions in standard MLR assays, could not be demonstrated. Suppressor cell activity, although not directly assayed, was not observed. Three objective tumors responses were seen in patients with renal cell carcinoma but none were seen in an adequately studied number of patients with advanced breast carcinoma, non-oat cell lung cancer, melanoma, or colon carcinoma. Alpha-1 serum levels of 10 to 25 ng/ml were achieved within one hour of the administration of 60-150 mg/m2 fraction 5. These pharmacologic levels were maintained for several hours before falling off to baseline levels by 24 hours.

AB - Thus, in 193 patients treated with a variety of schedules and with doses ranging from 0.6 to 960 mg/m2, fraction 5 could be administered without toxicity other than the allergic reactions noted at high repeated doses with the intermittent schedule. Significant and reproducible biologic response modification as defined by T-cell quantitation (as determined by E-rosette assay and flourescent antibody assays for T-cell surface antigens) and by lymphocyte blastogenesis to suboptimal or optimal concentrations of PHA and Con A, as well as reactions to allogeneic antigens under a variety of suboptimal and optimal conditions in standard MLR assays, could not be demonstrated. Suppressor cell activity, although not directly assayed, was not observed. Three objective tumors responses were seen in patients with renal cell carcinoma but none were seen in an adequately studied number of patients with advanced breast carcinoma, non-oat cell lung cancer, melanoma, or colon carcinoma. Alpha-1 serum levels of 10 to 25 ng/ml were achieved within one hour of the administration of 60-150 mg/m2 fraction 5. These pharmacologic levels were maintained for several hours before falling off to baseline levels by 24 hours.

UR - http://www.scopus.com/inward/record.url?scp=0021618296&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021618296&partnerID=8YFLogxK

U2 - 10.1016/0305-7372(84)90017-3

DO - 10.1016/0305-7372(84)90017-3

M3 - Article

VL - 11

SP - 69

EP - 84

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

SN - 0305-7372

IS - 1

ER -